Shandong Weigao Group Medical Polymer
Market Cap
HK$68.7b
Last Updated
2021/04/14 10:16 UTC
Data Sources
Company Financials +
Executive Summary
Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People’s Republic of China. More Details
Rewards
PE ratio (28.2x) is below the Medical Equipment industry average (28.5x)
Risk Analysis
No risks detected for 1066 from our risk checks.
Snowflake Analysis
Excellent balance sheet with acceptable track record.
Similar Companies
Share Price & News
How has Shandong Weigao Group Medical Polymer's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1066 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 1066's weekly volatility (7%) has been stable over the past year.
Market Performance
7 Day Return
-1.6%
1066
-0.7%
HK Medical Equipment
-2.5%
HK Market
1 Year Return
36.7%
1066
38.4%
HK Medical Equipment
26.4%
HK Market
Return vs Industry: 1066 underperformed the Hong Kong Medical Equipment industry which returned 48% over the past year.
Return vs Market: 1066 exceeded the Hong Kong Market which returned 29.5% over the past year.
Shareholder returns
| 1066 | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.6% | -0.7% | -2.5% |
| 30 Day | 21.4% | 6.6% | -1.8% |
| 90 Day | -0.7% | -9.3% | 0.5% |
| 1 Year | 37.8%36.7% | 39.8%38.4% | 31.2%26.4% |
| 3 Year | 223.1%210.2% | 198.8%185.6% | 6.0%-5.2% |
| 5 Year | n/a | 280.9%248.2% | 47.3%22.5% |
Long-Term Price Volatility Vs. Market
How volatile is Shandong Weigao Group Medical Polymer's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Shandong Weigao Group Medical Polymer undervalued compared to its fair value and its price relative to the market?
28.29x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 1066 (HK$15.16) is trading above our estimate of fair value (HK$12.81)
Significantly Below Fair Value: 1066 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 1066 is good value based on its PE Ratio (28.2x) compared to the HK Medical Equipment industry average (28.5x).
PE vs Market: 1066 is poor value based on its PE Ratio (28.2x) compared to the Hong Kong market (11.6x).
Price to Earnings Growth Ratio
PEG Ratio: 1066 is poor value based on its PEG Ratio (1.5x)
Price to Book Ratio
PB vs Industry: 1066 is overvalued based on its PB Ratio (3.3x) compared to the HK Medical Equipment industry average (3.1x).
Future Growth
How is Shandong Weigao Group Medical Polymer forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
18.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1066's forecast earnings growth (18.3% per year) is above the savings rate (1.5%).
Earnings vs Market: 1066's earnings (18.3% per year) are forecast to grow slower than the Hong Kong market (19.7% per year).
High Growth Earnings: 1066's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1066's revenue (16.2% per year) is forecast to grow faster than the Hong Kong market (13.8% per year).
High Growth Revenue: 1066's revenue (16.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1066's Return on Equity is forecast to be low in 3 years time (14.6%).
Past Performance
How has Shandong Weigao Group Medical Polymer performed over the past 5 years?
15.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1066 has high quality earnings.
Growing Profit Margin: 1066's current net profit margins (17.9%) are higher than last year (17.8%).
Past Earnings Growth Analysis
Earnings Trend: 1066's earnings have grown by 15.4% per year over the past 5 years.
Accelerating Growth: 1066's earnings growth over the past year (10%) is below its 5-year average (15.4% per year).
Earnings vs Industry: 1066 earnings growth over the past year (10%) underperformed the Medical Equipment industry 19.7%.
Return on Equity
High ROE: 1066's Return on Equity (11.7%) is considered low.
Financial Health
How is Shandong Weigao Group Medical Polymer's financial position?
Financial Position Analysis
Short Term Liabilities: 1066's short term assets (CNÂ¥14.1B) exceed its short term liabilities (CNÂ¥4.5B).
Long Term Liabilities: 1066's short term assets (CNÂ¥14.1B) exceed its long term liabilities (CNÂ¥4.5B).
Debt to Equity History and Analysis
Debt Level: 1066's debt to equity ratio (23.3%) is considered satisfactory.
Reducing Debt: 1066's debt to equity ratio has increased from 9.4% to 23.3% over the past 5 years.
Debt Coverage: 1066's debt is well covered by operating cash flow (52.3%).
Interest Coverage: 1066's interest payments on its debt are well covered by EBIT (53.2x coverage).
Balance Sheet
Dividend
What is Shandong Weigao Group Medical Polymer current dividend yield, its reliability and sustainability?
1.06%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 1066's dividend (1.07%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (1.97%).
High Dividend: 1066's dividend (1.07%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.01%).
Stability and Growth of Payments
Stable Dividend: 1066's dividend payments have been volatile in the past 10 years.
Growing Dividend: 1066's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (28.7%), 1066's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 1066's dividends in 3 years are forecast to be well covered by earnings (23.2% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.2yrs
Average management tenure
CEO
Rinan Cong (39 yo)
0.083
Tenure
Mr. Rinan Cong serves as Chief Executive Officer at Shandong Weigao Group Medical Polymer Company Limited since March 30, 2021. He joined the Company in August 2003. During August 2003 to December 2013, he...
Leadership Team
Experienced Management: 1066's management team is considered experienced (4.2 years average tenure).
Board Members
Experienced Board: 1066's board of directors are considered experienced (4.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Shandong Weigao Group Medical Polymer Company Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Shandong Weigao Group Medical Polymer Company Limited
- Ticker: 1066
- Exchange: SZSC
- Founded: 2000
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: HK$68.739b
- Shares outstanding: 4.52b
- Website: https://www.weigaogroup.com
Number of Employees
Location
- Shandong Weigao Group Medical Polymer Company Limited
- Torch Hi-Tech Science Park
- 18 Xingshan Road
- Weihai
- Shandong Province
- 264210
- China
Listings
Biography
Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People’s Republic of China. The company operates thr...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/14 10:16 |
| End of Day Share Price | 2021/04/13 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.